Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosisFotini Vogiatzi, Denis M. Schewe, Carina Lynn Gehlert et al.|Blood Advances|2022Cited by 20
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosisLennart Lenk, Denis M. Schewe, Irène Baccelli et al.|Blood|2024Cited by 20
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i> -rearranged ALL across all age groupsAlina Hartmann, Claudia D. Baldus, Lorenz Bastian et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell MalignanciesFotini Vogiatzi, Denis M. Schewe, Julia Heymann et al.|Blood|2018Cited by 0